Johnson & Johnson
Johnson & Johnson
Do you know what heart failure is? (Hint: It’s probably not what you think)
For American Heart Month, learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
Johnson & Johnson named a 2024 Fortune World’s Most Admired Company
The company makes the list for the 22nd year in a row, thanks to its dedication to innovation, social responsibility and more.
Is this the end of one-size-fits-all treatments for depression?
Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
Meet the 2023 winners of the Johnson Medal
Every year, the company bestows this honor on outstanding scientists or researchers whose perseverance makes medical innovation and advancement possible.
What you need to know about Johnson & Johnson’s 2023 third-quarter earnings
Check out this infographic breakdown of the company’s third-quarter 2023 performance, with key highlights from its Innovative Medicine and MedTech businesses.
5 things we now know about atrial fibrillation
More than 37.5 million people worldwide are affected by this common type of heart arrhythmia—and by 2050, the number of cases will increase by 60%. For American Heart Month, learn the facts behind this heart condition, plus one patient’s diagnosis story.
What if bariatric surgery were easier to perform—and recover from?
Learn how new technology from Johnson & Johnson aims to be a game-changer not only for patients, but for surgeons, too.
Could we be on the cusp of catching Alzheimer’s before it starts?
The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.
Behind the relentless pursuit of multiple myeloma cures
Johnson & Johnson has been dedicated to developing innovative treatments for blood cancers for nearly 20 years. Scientist Kodandaram “Ram” Pillarisetti is at the forefront of the company’s commitment to working toward its goal of one day eliminating the disease.
What you need to know about Johnson & Johnson’s 2023 second-quarter earnings
Check out this infographic breakdown of the company’s second-quarter 2023 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.